[1] Algoet M, Janssens S, Himmelreich U, et al.Myocardial ischemia-reperfusion injury and the influence of inflammation[J]. Trends Cardiovasc Med, 2023,33(6):357-366. [2] 许海华,徐明星,周昱和,等. 急性心肌梗死患者行PCI术后心力衰竭的影响因素及风险预测模型研究[J]. 中国循证心血管医学杂志,2024,16(2):205-207,226. [3] Collet JP, Thiele H, Barbato E, et al.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021,42(14):1289-1367. [4] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021,42(36):3599-3726. [5] Strijbis EM, Repovic P, Mostert J, et al.The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials[J]. Mult Scler, 2022,28(10):1606-1619. [6] 张罡. 急性心肌梗死(AMI)患者行PCI后1年内发生不良心血管事件(MACE)的危险因素及预测价值[D]. 内蒙古医科大学,2024. [7] Udell JA, Petrie MC, Jones WS, et al.Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction[J]. J Am Coll Cardiol, 2024,83(23):2233-2246. [8] 尹成龙,丁佳佳. 沙库巴曲缬沙坦与重组人脑利钠肽序贯治疗急性心力衰竭患者的效果及预后[J]. 实用心脑肺血管病杂志,2023,31(8):34-38. [9] 李静,边云飞. SGLT2抑制剂治疗射血分数保留的心力衰竭作用机制的研究进展[J]. 中西医结合心脑血管病杂志,2023,21(17):3193-3196. [10] 周帆. ARNI对心梗合并心衰患者心室重构影响的研究[D]. 长江大学,2023. [11] 易震宁,林明华. 美托洛尔缓释片联合替罗非班对老年AMI患者PCI术后心血管不良事件的影响[J]. 医学信息,2024,37(22):54-57. |